Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases

Inclusion criteria

• Male or female subjects, 21 years of age or older.
• Subjects with a history of degenerative retinal diseases such as RP.
• Subjects with a documented history of disease progression.
• Willing and able to return for all study visits.
• Willing and able to provide written informed consent for the Clinical Study.
• Subjects with a BCVA greater or equal to 20/16000 must have consistent fixation demonstrated by indirect ophthalmoscopy with a small circle of light and by consistent location of remaining central visual field detected by VFA.
• Study Arm A: The best corrected visual acuity must be between 20/16000 and HM as tested by ETDRS chart and ERG B wave amplitude.
• Study Arm B: The best-corrected visual acuity must be between 20/60 and 20/16000 and visual field of central 15 degrees (III static 30-2 protocol, 31.5 ASB background) greater than 10 dB loss, as determined by a Humphrey Instruments, Inc. Visual Field Analyzer (VFA).

Exclusion criteria

• Subjects with significant lens or corneal pathology (either history of or current) in the study eye other than retinal diseases.
• Subjects with high myopia in the study eye (axial length greater than or equal to 26.0 millimeters by ultrasound or spherical equivalent at the spectacle plane greater than -8.0 diopters.)
• Subjects whose retinal disease status has been stable for more than 90 days.
• Subjects with history of iritis or uveitis in either eye.
• Subjects who have monocular vision.
• Subjects with a history of retinal detachment or tear in either eye.
• Subjets with unstable IOP (i.e. > 30 mmHg in the past six months) or IOP of > 24 mm Hg at enrollment while under medical control. Subjects may be on topical medications to control their IOP.
• Subjects with an aphakic study ete or if pseudophakic, cataract extraction surgery more than 6 months prior to study enrollment.
• Subjects with a history of ocular trauma of any type in the study eye.
• Subjects with media opacities or abnormalities that would preclude observation of the retina in the study eye, per the investigator's judgement.
• Subjects that have undergone any previous vitrectomy (either anterior or pars plana vitrectomy in the study eye).
• Subjects with a history of cataract surgery complication in the study eye.
• Subjects that have undergone previous photocoagulation of the retina in the study eye.
• Subjects anticipated requiring cataract extraction in the study eye within the next six (6) months.
• Subjects with congenital eye malformations.
• Recurrent uveitis or history of uveitis in either eye.
• Macular edema or history of macular edema in the study eye where central macular thickness is greater than 275 microns by OCT at baseline.
• Ongoing ocular infection or inflammation in the study eye.
• Pregnant or nursing females.